No Data
Shanghai Haoyuan Pharmaceutical Co., Ltd. 2024 Annual Results Express Announcement
Shanghai Haoyuan Chemexpress Makes Adjustments to Cash Management Strategy
Haoyuan Pharmaceutical (688131.SH) plans to launch a restricted stock incentive plan for 3 million shares.
Haoyuan Pharmaceutical (688131.SH) announced the draft of the restricted stock incentive plan for 2025. This time, the company is...
Express News | Shanghai Haoyuan Chemexpress Says Key Shareholders Plan to Unload up to 4.51% Stake in Three Months
Market Participants Recognise Shanghai Haoyuan Chemexpress Co., Ltd.'s (SHSE:688131) Earnings Pushing Shares 27% Higher
China Merchants: The surge in ADC research and development is driving a significant increase in outsourcing demand, and the ADC CDMO market is thriving.
The surge in ADC research and development has driven a significant increase in outsourcing demand, with strong market demand for ADC CDMO. Currently, the market shows a dual drive of capacity expansion and technological iteration.
Shanghai Haoyuan Chemexpress Co., Ltd.'s (SHSE:688131) P/E Is Still On The Mark Following 31% Share Price Bounce